Note: As of October 17, 2023 this document will include updates for other respiratory diseases of public health concern, primarily influenza and respiratory syncytial virus (RSV).

Additionally, the “Guidelines and Technical documents” section [last updated July 26, 2023] will no longer be updated, but is archived as an appendix at the end of this document.

Moving forward, any news and guidance updates will be cycled through the New Content section below, as always with the dates of the latest additions bolded.

This document is a collation of resources for your reference. For official guidance on COVID-19, Influenza, and RSV in Ontario, please visit the Ministry of Health (COVID-19 | The Flu | RSV).

Table of Contents
New Content ........................................................................................................................................3
Public Health Agencies ....................................................................................................................3
  Public Health Agency of Canada | canada.ca ..................................................................................3
  BC Centre for Disease Control | bccdc.ca..............................................................................3
  Institut national de santé publique ..............................................................................................4
  CDC: Centers for Disease Control and Prevention | cdc.gov ......................................................4
  ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu ..................5
  FDA: U.S. Food & Drug Administration | fda.gov ....................................................................5
  UK Government | gov.uk .....................................................................................................................5
  World Health Organization | who.int ......................................................................................................6
  Other relevant government bodies / health care organizations ..............................................................6
  Center for Infectious Disease Research Policy | cidrap.umn.edu ................................................................6
  National Collaborating Centre for Environmental Health | ncceh.ca ..............................................7
Appendices.................................................................................................................. 8
Guidelines and Technical documents [ARCHIVED] .................................................. 8
Appendix I: General Guidelines [ARCHIVED] .......................................................... 8
  Ontario / Canada Main Page .................................................................................. 8
  Reopening/Rebuilding Guidelines ...................................................................... 8
  Vaccinations – General ...................................................................................... 9
  Vaccinations - Adverse Effects ......................................................................... 10
  Background Information/Case Definitions ..................................................... 10
  Laboratories ....................................................................................................... 11
  Miscellaneous Guidelines .................................................................................. 11
  Data & Surveillance ............................................................................................ 11
  Variants – Omicron ........................................................................................... 12
  Testing .................................................................................................................. 12
  Symptoms/Treatment ......................................................................................... 12
  COVID-19 Diagnosis in Children .................................................................... 13
  Post-COVID-19 Condition ............................................................................... 13
  Case Investigation & Contact Tracing .............................................................. 14
  Infection Prevention and Control .................................................................... 14
Appendix II: Guidelines for Health Sectors [ARCHIVED] .................................. 14
  Healthcare Providers ......................................................................................... 14
  Congregate Living (including Long-Term Care, Prisons, and Shelters) ......... 15
Appendix III: Guidelines for the Community [ARCHIVED] ................................ 15
  Travel, Transport & Borders ............................................................................ 15
  Schools / Childcare ........................................................................................... 16
  Mental Health/Substance Use Health ............................................................... 16
  Community/Workplaces .................................................................................... 17
New Content

Public Health Agencies

Public Health Agency of Canada | canada.ca
- COVID-19 epidemiology update: testing and variants [updated 01-16-2024]
- COVID-19 activity levels [updated 01-16-2024]
- Key COVID updates [updated 01-16-2024]
  - Weekly change in cases: 9,590
  - Total cases: 4,901,250
  - Weekly change in deaths: 126
  - Total deaths: 57,516
  - Weekly tests reported: 47,644
  - Weekly percent positivity: 14.5%
- NACI. Guidance on an additional dose of COVID-19 vaccines in the spring for individuals at high risk of severe illness due to COVID-19 [01-12-2024]
  - Summary of NACI statement of January 12, 2024: Guidance on an additional dose of COVID-19 vaccines in the spring of 2024 for individuals at high risk of severe illness due to COVID-19 [01-12-2024]
- Weekly influenza reports [updated 01-12-2024]
  December 31, 2023 to January 6, 2024 (week 1)
  - At the national level, influenza activity decreased this week but remain at elevated levels. Most surveillance indicators are decreasing and are within expected levels typical of this time of year.
    - Virologic
      - In week 1, the percentage of tests positive for influenza was 15.0% and a total of 6,215 laboratory detections (5,968 influenza A and 247 influenza B) were reported.
    - Syndromic
      - The percentage of visits for influenza-like illness (ILI) was 1.8% in week 1. The percentage of visits for ILI is within levels typical of this time of year.
      - The percentage of FluWatchers reporting cough and fever was 2.1% in week 1. The percentage of FluWatchers reporting cough and fever is within levels typical of this time of year.
- Respiratory virus report, week 1 - ending January 6, 2024 [updated 01-06-2024]
- COVID-19 daily epidemiology update [updated regularly]
- Respiratory virus detections in Canada [updated regularly]

BC Centre for Disease Control | bccdc.ca
- Respiratory epidemiology summary – week 1 [01-11-2024]
- Epi week 1: Dec 31, 2023 to Jan 6, 2024 [updated 01-11-2024]
  - Influenza A and RSV activity remain elevated; COVID-19 activity is variable across indicators, remaining relatively stable or slightly increasing over recent weeks.
- Genomic surveillance [updated 01-11-2024]
- Respiratory season reports [updated regularly]
  - Wastewater surveillance [updated 01-11-2024]
- **Acute care and long-term care outbreaks** [updated 01-11-2024]
- **Emergency department visits for respiratory illness in BC** [updated 01-11-2024]
- **Viral pathogen characterization** [updated 01-11-2024]
- **Primary care visits for respiratory illness** [updated 01-11-2024]

**COVID-19 situation report** [updated 01-04-2024]

**Respiratory surveillance report to health professionals in BC. Re: update: increased influenza activity and associated pediatric deaths in BC** [01-04-2024]

---

**Institut national de santé publique | inspg.qc.ca**

- Santé mentale et troubles mentaux courants en contexte de pandémie de la COVID-19 : état des lieux [01-11-2024]
- Les impacts de la pandémie de COVID-19 chez les jeunes de 14 à 17 ans du Québec [01-08-2024]

**CDC: Centers for Disease Control and Prevention | cdc.gov**

- **CDC tracks hospital capacity as respiratory diseases continue to spread** [01-12-2024]
- **This flu season could see more severe illness among children and older adults** [01-12-2024]
- **Weekly U.S. influenza surveillance report** [updated 01-12-2024]
  - Seasonal influenza activity remains elevated in most parts of the country.
  - After several weeks of increases in key flu indicators a single week of decrease has been noted. CDC will continue to monitor for a second period of increased influenza activity that often occurs after the winter holidays.
  - Outpatient respiratory illness has been above baseline\(^1\) nationally since November and is above baseline in all 10 HHS Regions.
  - The number of weekly flu hospital admissions decreased slightly.
  - During Week 1, of the 1,036 viruses reported by public health laboratories, 830 (80.1%) were influenza A and 206 (19.9%) were influenza B. Of the 511 influenza A viruses subtyped during Week 1, 407 (79.6%) were influenza A(H1N1) and 104 (20.4%) were A(H3N2).
  - Thirteen influenza-associated pediatric deaths were reported during Week 1, bringing the 2023-2024 season total to 40 pediatric deaths.
  - CDC estimates that there have been at least 14 million illnesses, 150,000 hospitalizations, and 9,400 deaths from flu so far this season.
  - CDC recommends that everyone 6 months and older get an annual flu vaccine as long as influenza viruses are spreading.\(^2\) Vaccination now can still provide benefit this season.
  - There also are prescription flu antiviral drugs that can treat flu illness; those should be started as early as possible and are especially important for higher risk patients.\(^3\)
- **Respiratory Virus Data Channel weekly snapshot** [updated 01-12-2024]
  - The amount of respiratory illness (fever plus cough or sore throat) causing people to seek healthcare is elevated or increasing across most areas of the country. This week, 37 jurisdictions experienced high or very high activity.
- **Severe viral respiratory illness** [updated 01-12-2024]
- **Respiratory virus activity levels** [updated 01-12-2024]
- **Groups most impacted—emergency department visits** [updated 01-12-2024]
- **Vaccination trends—children** [updated 01-12-2024]
- **COVID-19 activity increases as prevalence of JN.1 variant continues to rise** [01-05-2024]
- **COVID Data Tracker** [updated regularly]
- **Respiratory virus index** [updated regularly]

---

COVID-19, Influenza, & RSV: 01/16/2024

Compiled by PHO Library Services
By the end of week 1 (ending 7 January 2024), rates of respiratory illness (influenza-like illness (ILI) and/or acute respiratory infection (ARI)) in the community continue to increase in most EU/EEA countries. Rates of severe acute respiratory infection (SARI) cases presenting to secondary care due to seasonal influenza were at a level comparable to the same time last year and are now notably increasing in four of the seven reporting countries.

Consultation rates of patients presenting to general practitioners with respiratory illness (ILI and/or ARI) increased and since week 1, 2024, the majority of EU/EEA countries report activity above baseline. Seasonal influenza is circulating at higher levels than SARS-CoV-2 and respiratory syncytial virus (RSV), which are both declining in activity. Of 24 countries reporting testing for influenza, 17 reported seasonal influenza activity above the 10% positivity threshold in sentinel primary care in week 1. Concurrently, an increasing number of countries reported the geographical spread as widespread, indicating that influenza activity is intensifying. Influenza median test positivity has continued to increase to 26% (pooled country data: 28%) in week 1. Influenza activity began later in 2023–2024 than in 2022–2023. Countries report a mix of increasing and decreasing trends in SARS-CoV-2 activity and COVID-19 hospitalisations, ICU admissions and deaths, with severe outcomes predominantly among those aged 65 years and above. For RSV, countries continue to report a mix of increasing and decreasing trends for activity and severity indicators. The highest impact of RSV continues to be among children aged 0–4 years. Due to decreased testing and reporting during the holiday period, data for week 51 in 2023 to week 1 in 2024 must be interpreted with caution.
- National flu and COVID-19 surveillance reports: 2023 to 2024 season [updated 01-11-2024]
- UKHSA and ONS release latest Winter COVID-19 Infection Study Data [updated 01-11-2024]

- UK Office for Health Improvement and Disparities
  - Excess mortality in England and English regions analysis estimating excess mortality during and after the COVID-19 pandemic [updated 12-21-2023]

**World Health Organization | who.int**

- Epidemiological update: SARS-CoV-2 and other respiratory viruses in the Americas region - 8 January 2024 [01-08-2024]
- Influenza virus characterization: summary report, Europe, December 2023 [01-08-2024]

**Other relevant government bodies / health care organizations**

- Canadian Centre for Occupational Health and Safety
  - COVID-19 health and safety resources [updated regularly]
- Government of Ontario
  - COVID-19 vaccines [updated 10-30-2023]
- Health Canada
  - Novavax Nuvaxovid COVID-19 vaccine [updated 12-05-2023]
- Statistics Canada
  - Preliminary dataset on confirmed cases of COVID-19, Public Health Agency of Canada [01-12-2024]
  - Detailed preliminary information on cases of COVID-19, 2020-2024: 4-Dimensions (Aggregated data), Public Health Agency of Canada [01-12-2024]
  - Detailed preliminary information on cases of COVID-19, 2020-2024: 5-Dimensions (Aggregated data), Public Health Agency of Canada [01-12-2024]
  - Detailed preliminary data on confirmed cases of COVID-19, January 15, 2020, to January 4, 2024 (revised data) [01-12-2024]
  - Experiences of Canadians with long-term symptoms following COVID-19 [01-08-2024]
  - A snapshot of the health of Canadians [11-29-2023]

**Center for Infectious Disease Research Policy | cidrap.umn.edu**

- US respiratory virus levels remain high amid possible post-holiday spike [01-12-2024]
- More evidence vaccination reduces risk of long COVID [01-12-2024]
• Risk of death 3 times higher in Brazilian kids with COVID-19 than with other respiratory viruses, study finds [01-12-2024]
• Bivalent vaccines help prevent COVID-related stroke, heart attack, US data show [01-11-2024]
• Study: Confusing government COVID reporting requirements led to disparities in hospital data sharing [01-11-2024]
• COVID vaccine performed well at preventing hospital illness in teens [01-11-2024]
• Study suggests people who limit meat 40% less likely to get COVID, but some experts skeptical [01-10-2024]
• Racial differences in school enrollment during COVID spotlighted [01-09-2024]
• Bivalent COVID vaccine very effective against severe illness in children, study concludes [01-09-2024]
• Nearly two thirds of Korean SARS-CoV-2 cohort had long COVID at 2 years [01-09-2024]
• Some Southern Hemisphere countries experiencing rise in COVID [01-09-2024]

National Collaborating Centre for Environmental Health | ncceh.ca
• August 2023 environmental health research scan [08-01-2023]
• July 2023 environmental health research scan [07-01-2023]

COVID-END | www.mcmasterforum.org/networks/covid-end
• Global spotlight 27.1: key additions for March 2023 [03-30-2023]

ProMED | promedmail.org
• Latest on COVID-19 [individual posts]
• COVID-19 update (05): Pakistan, JN.1, variant of interest [01-10-2024]
• COVID-19 update (04): selected locations, JN.1 virology, severity, omicron BA.4.1 in dogs [01-10-2024]
• Influenza (02): Morocco, susp, children, RFI [01-06-2024]
• COVID-19 update (03): Israel, JN.1, new variant [01-03-2024]

Data & Real-time Tracking

COVID-19 resources (case counts) | arcgis.com
• Canada COVID-19 Note: has ceased updates as of 07-03-2023

COVID-19 Canada Open Data Working Group | COVID-19 CODWG
• COVID-19 in Canada (case count dashboard)

Johns Hopkins CCSE | systems.jhu.edu
• 2019-nCoV Global Cases (by Johns Hopkins CSSE)

NextStrain | nextstrain.org
• Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV)
• Genomic epidemiology of novel coronavirus (nCoV)
• Genomic analysis of nCoV spread. Situation report 2020-01-30

WHO | who.int
• WHO coronavirus (COVID-2019) dashboard

Appendices

Guidelines and Technical documents [ARCHIVED]
The guidelines were last updated 07-26-2023; news and updated guidance can be found in the New Content section above.

Appendix I: General Guidelines [ARCHIVED]
Ontario / Canada Main Page
• Ontario guidance
• Canadian guidance (federal)

Reopening/Rebuilding Guidelines

Ontario
• ON Protection from COVID-19 and other respiratory illnesses [updated 06-15-2023]

Canada (federal) and provinces and territories (other than Ontario)
• CA Guidance for a strategic approach to lifting restrictive public health measures [06-10-2022]
• CA COVID-19: readiness criteria and indicators for easing restrictive public health measures [05-14-2021]
• BC B.C.'s response to COVID-19 [updated 02-11-2023]
• AB COVID-19 public health actions [no date]
• SK Living with COVID [no date]
• MB COVID-19 Novel Coronavirus [no date]
• QC Coronavirus disease (COVID-19) in Québec [updated 07-20-2023]
• NB Living with COVID-19 [no date]
• NL NL life with COVID-19 [no date]
• PEI COVID-19 [no date]
• NS Government’s response to COVID-19 [updated regularly]
• NW COVID-19 [no date]
• YT Forging ahead: the Yukon's continuing response to COVID-19 [no date]
• NT Nunavut’s Path: living with COVID-19 [no date]
• National Collaborating Centre for Indigenous Health (NCCIH): Guidance on re-opening northern, remote, isolated, and Indigenous communities [2020]
WHO

- **End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance: compendium of country approaches** [08-02-2023]
- **Considerations for implementing and adjusting public health and social measures in the context of COVID-19: interim guidance** [03-30-2023]

ECDC

- **Conducting after-action reviews of the public health response to COVID-19: update** [03-21-2023]

Vaccinations – General

Ontario Ministry of Health

- **COVID-19 vaccine-relevant information and planning resources** [updated 07-13-2023]

Canada (Federal)

- **Planning guidance for immunization clinics for COVID-19 vaccines** [updated 03-06-2023]
- **For immunization providers: Interim national vaccine storage, handling and transportation guidelines for ultra-low temperature and frozen temperature COVID-19 vaccines** [updated 07-31-2023]
- **Guidance on the use of COVID-19 vaccines in the fall of 2023** [updated 07-11-2023]
- **Interim guidance on the use of bivalent Omicron-containing COVID-19 vaccines for primary series** [updated 07-05-2023]
- **Summary of updates in the Canadian Immunization Guide as of June 27, 2023: Updated guidance on COVID-19 vaccines in Canada** [updated 06-27-2023]

Provinces and territories (other than Ontario)

- **BC COVID-19 vaccine eligibility** [updated 08-01-2023]

CDC

- **Stay up to date with COVID-19 vaccines including boosters** [updated 07-17-2023]
- **COVID-19 vaccines for specific groups of people** [updated 06-29-2023]

UK

- **COVID-19 vaccination programme** [updated 08-08-2023]
- **COVID-19 vaccination: vaccine product information** [07-18-2023]
- **COVID-19: the green book, chapter 14a** [04-27-2023]

ECDC

- **Interim public health considerations for COVID-19 vaccination roll-out during 2023** [04-05-2023]
- **Interim analysis of COVID-19 vaccine effectiveness against severe acute respiratory infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – third update** [modified 03-16-2023]
- **Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA.** [updated 03-03-2023]

Australia

- **COVID-19 booster vaccine advice** [updated 04-05-2023]
- **Clinical recommendations for COVID-19 vaccines** [updated 03-21-2023]
- **ATAGI clinical guidance for COVID-19 vaccine providers** [updated 02-17-2023]
Vaccinations - Adverse Effects

Canada (Federal)
- Reporting ocular adverse events following COVID-19 vaccination: Communiqué to healthcare professionals (May 30, 2022) [05-30-2022]

Provinces and territories (other than Ontario)

CDC
- Reported adverse events [updated 07-13-2023]

WHO
- Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19) [03-31-2023]

UK
- Coronavirus (COVID-19) vaccines adverse reactions [updated 03-08-2023]
- Myocarditis and pericarditis after COVID-19 vaccination [updated 01-09-2023]

Australia
- ATAGI clinical guidance on COVID-19 vaccine administration errors [updated 06-05-2023]

Background Information/Case Definitions

Ontario Ministry of Health
- Ontario case definition - coronavirus disease (COVID-19) [updated 05-00-2023]

PHAC
- National case definition: coronavirus disease (COVID-19) [updated 06-06-2023]

CDC
- Coronavirus disease 2019 (COVID-19) 2023 case definition [reviewed 02-28-2023]

WHO
- WHO COVID-19 Case definition [updated 07-22-2022]
- A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 [10-06-2021]

ECDC
- Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA [04-08-2021]

UK
- COVID-19: epidemiology, virology and clinical features [05-17-2022]

Australia
- COVID-19 disease, symptoms and variants [updated 12-09-2022]
Other
- BMJ best practice COVID-19 [updated regularly]

Laboratories

Ontario Ministry of Health
- Management of cases and contacts of COVID-19 in Ontario (version 15.2) [06-09-2023]

PHAC
- Requirements for serological antibody tests submitted under the COVID-19 interim order: guidance [modified 02-22-2023]

CDC

Miscellaneous Guidelines

PHAC
- COVID-19 and people with disabilities in Canada [updated 01-30-2023]
- Individual public health measures [updated 01-27-2023]
- Summary of evidence supporting COVID-19 public health measures [updated 01-27-2023]

CDC
- CDC Archive: Archived web material for CDC.gov is preserved on the CDC Archive Site. Note that the content on this site is for historical purposes only and is no longer being updated. The information here may be outdated and links may no longer function.

WHO
- Considerations in adjusting public health and social measures in the context of COVID-19: interim guidance [updated 03-30-2023]

Data & Surveillance

Canada
- COVID-19 data trends [modified 03-06-2023]
- National surveillance guidelines for coronavirus disease (COVID-19) [03-19-2021]

WHO

CDC
- COVID-19 serology surveillance [03-11-2021]

ECDC
- Organisation of vector surveillance and control in Europe [12-13-2021]
- Surveillance of COVID-19 in long-term care facilities in the EU/EEA [11-29-2021]
Variants – Omicron

Canada
- SARS-CoV-2 variants: national definitions, classifications and public health actions [08-18-2022]

CDC
- What is genomic surveillance? [updated 12-02-2022]

UK
- Investigation of SARS-CoV-2 variants [updated 03-10-2023]
- SARS-CoV-2 variants of public health interest [updated 03-10-2023]

ECDC
- Methods for the detection and characterisation of SARS-CoV-2 variants – second update [08-02-2022]

Testing

Canada
- Interim guidance on the use of rapid antigen detection tests for the identification of SARS-CoV-2 infection [07-07-2022]

Ontario Ministry of Health
- Management of cases and contacts of COVID-19 in Ontario Version 15.2 [03-27-2023]
- COVID-19 provincial testing guidance. Version 15.3 [01-25-2023]

Canadian provinces and territories (other than Ontario)

WHO
- Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing [03-09-2022]

CDC
- Guidance for healthcare workers about COVID-19 (SARS-CoV-2) testing [updated 12-20-2022]
- Using antibody tests for COVID-19 [updated 12-16-2022]

UK
- Investigation of SARS-CoV-2 variants: technical briefings [updated 02-10-2023]
- SARS-CoV-2 variants of public health interest [updated 02-10-2023]

ECDC
- Methods for the detection and identification of SARS-CoV-2 variants- first update [08-02-2022]

Symptoms/Treatment

Canada

Ontario Ministry of Health
- Management of cases and and contacts of COVID-19 in Ontario version 15.2 [updated 03-27-2023]

BC
- Clinical practice guide for the use of therapeutics in mild-moderate COVID-19 [updated 01-10-2023]
WHO
- WHO living guideline: drugs to prevent COVID-19 [updated 03-24-2023]

CDC
- Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare providers [updated 02-09-2023]
- Clinical care information for COVID-19 [updated 01-30-2023]
- Clinical considerations for care of children and adults with confirmed COVID-19 [updated 01-27-2023]
- Clinical considerations for care of children and adults with confirmed COVID-19 [updated 01-27-2023]
- Care for breastfeeding people: interim guidance on breastfeeding and breast milk feeds in the context of covid-19 [02-25-2022]

US NIH
- COVID-19 treatment guidelines [updated 03-06-2023]

UK
- Find help and support if you have long COVID [updated 03-29-2023]

COVID-19 Diagnosis in Children
Canada

WHO
- A clinical case definition for post COVID-19 condition in children and adolescents by expert consensus [02-16-2023]

CDC
- Information for Pediatric Healthcare Providers [02-10-2023]

Other
- American Academy of Pediatrics What is the case definition of multisystem inflammatory syndrome in children (MIS-C) interim guidance [02-08-2023]

Post-COVID-19 Condition
Canada
- Post COVID-19 condition (long COVID) [modified 03-09-2023]

Ontario
- Ontario Health Post COVID-19 condition: guidance for primary care [12-00-2022]

WHO
- Post COVID-19 condition [12-16-2021]
CDC
- Post-COVID conditions; CDC Science [updated 03-31-2023]

UK
- Long-term effects of coronavirus (long COVID) [reviewed 03-21-2023]

Case Investigation & Contact Tracing

Canada
- Public health management of cases and contacts associated with COVID-19 [01-30-2023]

Ontario
- Management of cases and contacts of COVID-19 in Ontario (version 15.2) [03-27-2022]

CDC
- Isolation and precautions for people with COVID-19 [03-21-2023]

UK
- COVID-19 rapid guideline: managing COVID-19 NICE guideline [NG191] [03-29-2023]

Infection Prevention and Control

PHAC / Health Canada
- At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19 [01-27-2023]
- Coronavirus disease (COVID-19): prevention and risks [01-27-2023]
- COVID-19 mask use: advice for community settings [01-30-2023]

Ontario
- COVID-19 guidance: personal protective equipment (PPE) for health care workers and health care entities version 1.0 [06-10-2022]

Canadian provinces and territories (other than Ontario)

WHO

ECDC
- Considerations for infection prevention and control practices in relation to respiratory viral infections in healthcare settings [02-06-2023]

Appendix II: Guidelines for Health Sectors [ARCHIVED]

Healthcare Providers

Ontario Ministry of Health
- Management of cases and and contacts of COVID-19 in Ontario version 15.2 [03-27-2023]
- COVID-19 guidance: acute care v.9 [01-11-2023]
• COVID-19 guidance: personal protective equipment (PPE) for health care workers and health care entities version 1.0 [06-10-2022]

UK
• COVID-19: managing healthcare staff with symptoms of a respiratory infection [03-31-2023]

ECDC
• Considerations for infection prevention and control practices in relation to respiratory viral infections in healthcare settings [02-06-2023]
• Living safely with respiratory infections, including COVID-19: when to consider wearing a face covering or a face mask [06-16-2022]

Congregate Living (including Long-Term Care, Prisons, and Shelters)

Ontario Ministry of Health
• COVID-19 guidance document for long-term care homes in Ontario [04-03-2023]
• COVID-19 guidance: long-term care homes and retirement homes for public health units Version 10 [03-31-2023]

PHAC
• Infection prevention and control for COVID-19: interim guidance for long term care homes [01-25-2022]

CDC
• Guidance on management of COVID-19 in homeless service sites and in correctional and detention facilities [11-29-2022]

UK
• Acute respiratory illness, including flu and COVID-19 in prisons [04-06-2023]
• Infection prevention and control in adult social care: COVID-19 supplement [04-06-2023]
• COVID-19: outbreaks in prisons, refuges and other higher-risk accommodation settings [04-04-2023]

Other
• CSC Testing of inmates in federal correctional institutions for COVID-19 [04-12-2023]
COVID-19 travel recommendations by destination [updated regularly]
Stay up to date with your COVID-19 vaccines including Boosters [04-06-2023]

COVID-19: guidance for people whose immune system means they are at higher risk [03-14-2023]

Schools / Childcare

Ontario Ministry of Health

Management of cases and contacts of COVID-19 in Ontario version 15.2 [03-27-2023]
COVID-19: health and safety measures for child care [08-17-2022]
COVID-19: health and safety measures at schools [08-15-2022]

PHAC

Evaluating COVID-19 disease transmission and public health measures in schools: outbreak investigation guidance [07-22-2022]

CDC

Operational Guidance for K-12 Schools and Early Care and Education Programs to Support Safe In-Person Learning [10-05-2022]
Schools, child care, and colleges [10-25-2022]

UK


Mental Health/Substance Use Health

Ontario Ministry of Health

COVID-19 guidance: mental health and addictions service providers in community settings: version 2 [09-24-2020]

PHAC

Helping people who use substances [10-01-2022]

Provinces & Territories (excluding Ontario)

QC The roles of public health in population mental health and wellness promotion [10-03-2022]
BC COVID-19: harm reduction and overdose response [01-07-2022]
QC Housing and social inequalities in health in times of COVID-19: strategies for promoting affordable quality housing [04-05-2022]
QC Preventing violence and suicide within the context of the COVID-19 pandemic: courses of action [04-05-2022]
QC Preventing loneliness in young adults in the context of a pandemic [04-05-2022]
BC Impacts of the COVID-19 pandemic on the health and wellbeing of young adults in British Columbia [07-00-2021]
QC Public health ethics and COVID-19: selected resources [11-00-2021]
WHO
- Mental health and COVID-19: early evidence of the pandemic’s impact: scientific brief, 2 March 2022 [03-02-2022]

Community/Workplaces
Ontario Ministry of Health
- Protection from COVID-19 and other respiratory illnesses [04-12-2023]
- COVID-19 and workplace health and safety [03-09-2023]
- COVID-19 and your employment standards protections [06-26-2022]
- Outbreak guidance: workplace and living settings for seasonal international agriculture workers (IAWs) [09-08-2022]

PHAC
- Summary of evidence supporting COVID-19 public health measures [01-27-2023]
- Community based public health measures [01-27-2023]
- How businesses and employees can stay safe while operating during COVID-19 [01-27-2023]
- Accessing public health support for First Nations communities [08-05-2022]
- COVID-19 and people with disabilities in Canada [01-30-2023]
- COVID-19 mask use: advice for community settings [01-30-2023]

WHO
- The generic all-hazards risk assessment and planning tool for mass gathering events [01-12-2023]

CDC
- Specific settings [12-07-2022]

UK
- Infection prevention and control in adult social care: COVID-19 supplement [04-04-2023]
- Living safely with respiratory infections, including COVID-19 [06-16-2022]

Other
- CCOHS daycares [07-14-2022]